FR2215946A1 - Inactivating viruses for vaccine prodn. - by freez-drying in presence of protein stabilizer then heating - Google Patents

Inactivating viruses for vaccine prodn. - by freez-drying in presence of protein stabilizer then heating

Info

Publication number
FR2215946A1
FR2215946A1 FR7403925A FR7403925A FR2215946A1 FR 2215946 A1 FR2215946 A1 FR 2215946A1 FR 7403925 A FR7403925 A FR 7403925A FR 7403925 A FR7403925 A FR 7403925A FR 2215946 A1 FR2215946 A1 FR 2215946A1
Authority
FR
France
Prior art keywords
virus
esp
strain
mins
freez
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
FR7403925A
Other languages
English (en)
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wellcome Foundation Ltd
Original Assignee
Wellcome Foundation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellcome Foundation Ltd filed Critical Wellcome Foundation Ltd
Publication of FR2215946A1 publication Critical patent/FR2215946A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/165—Mumps or measles virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10161—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16061—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
    • C12N2760/18661—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18811—Sendai virus
    • C12N2760/18861—Methods of inactivation or attenuation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
FR7403925A 1973-02-07 1974-02-06 Inactivating viruses for vaccine prodn. - by freez-drying in presence of protein stabilizer then heating Withdrawn FR2215946A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB593673 1973-02-07

Publications (1)

Publication Number Publication Date
FR2215946A1 true FR2215946A1 (en) 1974-08-30

Family

ID=9805407

Family Applications (1)

Application Number Title Priority Date Filing Date
FR7403925A Withdrawn FR2215946A1 (en) 1973-02-07 1974-02-06 Inactivating viruses for vaccine prodn. - by freez-drying in presence of protein stabilizer then heating

Country Status (8)

Country Link
JP (1) JPS49109520A (enExample)
AU (1) AU6525274A (enExample)
BE (1) BE810697A (enExample)
DE (1) DE2405675A1 (enExample)
ES (1) ES422966A1 (enExample)
FR (1) FR2215946A1 (enExample)
IL (1) IL44143A0 (enExample)
NL (1) NL7401610A (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0028563A1 (en) * 1979-10-29 1981-05-13 Merck & Co. Inc. Stabilizer for liquid vaccines and liquid vaccine containing said stabilizer
EP0030199A3 (en) * 1979-12-03 1982-06-09 Merck & Co. Inc. Lyophilization process for live viral compositions
FR2505657A1 (fr) * 1981-05-13 1982-11-19 Pasteur Institut Perfectionnements apportes aux agents de stabilisation de virus vivants pour la preparation de vaccins, et vaccins stabilises contenant lesdits agents de stabilisation
FR2532548A1 (fr) * 1982-09-03 1984-03-09 Pasteur Institut Nouveau procede de production de vaccins presentant un titre eleve de virus et vaccins tres purifies, a titre eleve de virus, ainsi obtenus

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL191729C (nl) * 1978-04-12 1996-05-03 Merck & Co Inc Gestabiliseerd vaccin.
JPS57114527A (en) * 1979-10-29 1982-07-16 Merck & Co Inc Vaccine stabilizer
US4338335A (en) * 1980-02-05 1982-07-06 Merck & Co., Inc. Vaccine stabilizer containing L-glutamic acid and L-arginine
US4337242A (en) * 1980-02-05 1982-06-29 Merck & Co., Inc. Vaccine stabilizer containing L-glutamic acid and L-arginine
JPS577423A (en) * 1980-06-13 1982-01-14 Takeda Chem Ind Ltd Frozen or freeze-dried live measles vaccine
US4695454A (en) * 1985-04-01 1987-09-22 New York Blood Center, Inc. Process for preparing hepatitis B surface antigen containing particles in novel forms which are highly immunogenic
JPH0759759B2 (ja) * 1988-10-29 1995-06-28 株式会社日立製作所 焼鈍されたステンレス鋼帯の脱スケール方法及び装置
US7682619B2 (en) 2006-04-06 2010-03-23 Cornell Research Foundation, Inc. Canine influenza virus

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0028563A1 (en) * 1979-10-29 1981-05-13 Merck & Co. Inc. Stabilizer for liquid vaccines and liquid vaccine containing said stabilizer
EP0030199A3 (en) * 1979-12-03 1982-06-09 Merck & Co. Inc. Lyophilization process for live viral compositions
FR2505657A1 (fr) * 1981-05-13 1982-11-19 Pasteur Institut Perfectionnements apportes aux agents de stabilisation de virus vivants pour la preparation de vaccins, et vaccins stabilises contenant lesdits agents de stabilisation
EP0065905A1 (fr) * 1981-05-13 1982-12-01 Institut Pasteur Perfectionnements apportés aux agents de stabilisation de virus vivants pour la préparation de vaccins, et vaccins stabilisés contenant lesdits agents de stabilisation
US4500512A (en) * 1981-05-13 1985-02-19 Institut Pasteur Stabilizing agents for live viruses for preparing vaccines, and stabilized vaccines containing said stabilizing agents
FR2532548A1 (fr) * 1982-09-03 1984-03-09 Pasteur Institut Nouveau procede de production de vaccins presentant un titre eleve de virus et vaccins tres purifies, a titre eleve de virus, ainsi obtenus

Also Published As

Publication number Publication date
JPS49109520A (enExample) 1974-10-18
DE2405675A1 (de) 1974-08-15
NL7401610A (enExample) 1974-08-09
ES422966A1 (es) 1976-06-01
IL44143A0 (en) 1974-05-16
BE810697A (fr) 1974-08-06
AU6525274A (en) 1975-08-07

Similar Documents

Publication Publication Date Title
FR2215946A1 (en) Inactivating viruses for vaccine prodn. - by freez-drying in presence of protein stabilizer then heating
US3755557A (en) Spray vaccines
Furuya et al. Effect of inactivation method on the cross-protective immunity induced by whole ‘killed’influenza A viruses and commercial vaccine preparations
US20040053316A1 (en) Methods and compositions for the selective modification of nucleic acids
JPS6259088B2 (enExample)
JPS6230752B2 (enExample)
FI102616B1 (fi) Menetelmä rokotteen valmistamiseksi ihmisen parainfluenssa-viruksen tyyppiä 3 varten ja menetelmässä käytettävä ilmentämisjärjestelmä
Wraith et al. Induction of influenza A virus cross-reactive cytotoxic T cells by a nucleoprotein/haemagglutinin preparation
Morein et al. Protein subunit vaccines of parainfluenza type 3 virus: immunogenic effect in lambs and mice
ES355121A1 (es) Procedimiento para la preparacion de una vacuna libre de antigenos.
CA1049406A (en) Isolation of hemagglutinin and neuraminidase from influenza virus
Sinkovics et al. Some properties of the photodynamically inactivated Rauscher mouse leukemia virus
De Jong et al. Inactivation of encephalomyocarditis virus in aerosols: fate of virus protein and ribonucleic acid
GB1442564A (en) Process for preparing inactivated hb ag vaccine
Balcarova et al. Antibody response to spike protein vaccines prepared from Semliki Forest virus
ATE1044T1 (de) Impfstoff gegen infektioese peritonitis der feliden und verfahren zu seiner herstellung.
Nagieva et al. Characterization of markers of cold-adapted candidate virus strains for live attenuated vaccines against chickenpox and shingles
FR2270892A1 (en) Vaccines from attenuated viruses - which have been serially incubated with yeast cells, especially Saccharomyces cerevisiae
Mekler et al. Sendai virus RNA as messenger RNA determining the synthesis of early virus specific proteins
Polley Preparation of a stable non-infective complement-fixing antigen for herpes simplex
Nakamura A comparison of the yields of infectious ribonucleic acid from heated and ultraviolet irradiated mouse encephalomyelitis virus (GDVII strain)
RU1822791C (ru) Способ получени инактивированной гриппозной вакцины
US3629470A (en) Process for purification of animal rna viruses
CA2006078A1 (en) Method for disrupting virus particles
FR2261779A1 (en) Anti-rabies vaccine - obtd. from rabies virus grown on foetal calf kidney cells in a synthetic serum-free medium

Legal Events

Date Code Title Description
ST Notification of lapse